Douglas Forsyth Biography and Net Worth

Director of Inhibrx Biosciences

Mr. Forsyth has served as a member of our Board since April 2018. From 1994 until February 2022, Mr. Forsyth served as a portfolio manager, a managing director and Chief Investment Officer of U.S. Income & Growth Strategies with Allianz Global Investors GmbH (“Allianz”). Mr. Forsyth was also the head of the Allianz Income and Growth Strategies team, during which time he had portfolio management, trading and research responsibilities, and oversaw all aspects of the Income and Growth platform’s business, including product development and implementation. Mr. Forsyth was the lead portfolio manager for the Allianz U.S. High Yield Bond strategy since its inception in August 1994 and assumed lead portfolio management responsibility for the firm’s U.S. Convertible strategy in 1998. In addition to management responsibility for institutional clients worldwide, Mr. Forsyth supervised multiple open-end and closed-end mutual funds. Mr. Forsyth has 30 years of investment-industry experience. Mr. Forsyth currently serves, or has served, on a variety of non-public company boards across a variety of industries as well as several charitable boards. Mr. Forsyth received a Bachelor of Business Administration from the University of Iowa.

What is Douglas Forsyth's net worth?: The estimated net worth of Douglas Forsyth is at least $26.55 million as of September 8th, 2026. Mr. Forsyth owns 227,064 shares of Inhibrx Biosciences stock worth more than $26,550,366 as of September 9th. This net worth evaluation does not reflect any other assets that Mr. Forsyth may own. Learn More about Douglas Forsyth's net worth.
How do I contact Douglas Forsyth?: The corporate mailing address for Mr. Forsyth and other Inhibrx Biosciences executives is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. Inhibrx Biosciences can also be reached via phone at 858-795-4220 and via email at [email protected]. Learn More on Douglas Forsyth's contact information.
Has Douglas Forsyth been buying or selling shares of Inhibrx Biosciences?: In the last ninety days, Douglas Forsyth has bought $286,625.00 in shares of Inhibrx Biosciences stock. Most recently, on Tuesday, September 8th, Douglas Forsyth bought 2,500 shares of Inhibrx Biosciences stock. The stock was acquired at an average cost of $114.65 per share, with a total value of $286,625.00. Following the completion of the transaction, the director now directly owns 227,064 shares of the company's stock, valued at $26,032,887.60. Learn More on Douglas Forsyth's trading history.
Who are Inhibrx Biosciences' active insiders?: Inhibrx Biosciences' insider roster includes Brendan Eckelman (Insider), Douglas Forsyth (Director), Jeffrey Jensen (EVP & Chief Clinical Devel. Officer), Jon Kayyem (Director), Mark Lappe (Founder), Mark Lappe (CEO), and Kristiina Vuori (Director). Learn More on Inhibrx Biosciences' active insiders.
Are insiders buying or selling shares of Inhibrx Biosciences?: During the last twelve months, Inhibrx Biosciences insiders bought shares 3 times. They purchased a total of 32,500 shares worth more than $3,499,725.00. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 350,000 shares worth more than $11,287,500.00. The most recent insider tranaction occured on September, 8th when Director Douglas Forsyth bought 2,500 shares worth more than $286,625.00. Insiders at Inhibrx Biosciences own 18.3% of the company. Learn More about insider trades at Inhibrx Biosciences.
Information on this page was last updated on 9/8/2026.

Douglas Forsyth Insider Trading History at Inhibrx Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/8/2026	Buy	2,500	$114.65	$286,625.00	227,064

Douglas Forsyth Buying and Selling Activity at Inhibrx Biosciences

Inhibrx Biosciences Company Overview

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Today's Range

Now: $115.11

$113.57

$128.54

50 Day Range

MA: $98.17

$79.25

$126.70

2 Week Range

Now: $115.11

$26.19

$155.29

Volume

515,172 shs

Average Volume

320,869 shs

Market Capitalization

$1.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.66